Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at HC Wainwright lifted their Q2 2025 EPS estimates for shares of Entrada Therapeutics in a note issued to investors on Tuesday, May 20th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.98) per share for the quarter, up from their prior estimate of ($1.00). HC Wainwright has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Entrada Therapeutics' current full-year earnings is $1.12 per share. HC Wainwright also issued estimates for Entrada Therapeutics' Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($1.19) EPS, FY2025 earnings at ($3.65) EPS and Q1 2026 earnings at ($1.13) EPS.
Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.36. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. The company had revenue of $8.75 million for the quarter, compared to the consensus estimate of $10.98 million.
Entrada Therapeutics Price Performance
Shares of Entrada Therapeutics stock traded up $0.20 during trading on Thursday, reaching $7.70. 40,643 shares of the company traded hands, compared to its average volume of 130,644. The firm has a market capitalization of $292.24 million, a PE ratio of 4.84 and a beta of 0.04. The company has a 50 day moving average price of $8.57 and a 200-day moving average price of $12.94. Entrada Therapeutics has a 1-year low of $7.10 and a 1-year high of $21.79.
Hedge Funds Weigh In On Entrada Therapeutics
Large investors have recently modified their holdings of the company. KLP Kapitalforvaltning AS purchased a new position in shares of Entrada Therapeutics in the fourth quarter worth $36,000. BNP Paribas Financial Markets bought a new stake in shares of Entrada Therapeutics during the 4th quarter valued at $57,000. Virtus ETF Advisers LLC bought a new position in Entrada Therapeutics in the 4th quarter worth about $68,000. AlphaQuest LLC bought a new position in Entrada Therapeutics in the 4th quarter worth about $70,000. Finally, Russell Investments Group Ltd. lifted its stake in Entrada Therapeutics by 53,455.6% during the 4th quarter. Russell Investments Group Ltd. now owns 4,820 shares of the company's stock valued at $83,000 after acquiring an additional 4,811 shares during the period. 86.39% of the stock is currently owned by institutional investors.
About Entrada Therapeutics
(
Get Free Report)
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Featured Stories
Before you consider Entrada Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entrada Therapeutics wasn't on the list.
While Entrada Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
